Aptitude Receives FDA Authorization for Metrix® COVID/Flu Multiplex Molecular Test for Point-of-Care and Over-the-Counter Use

SANTA BARBARA, Calif., Feb. 24, 2025 /PRNewswire/ -- Aptitude Medical Systems, Inc. (Aptitude) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its next-gen molecular Metrix® COVID/Flu multiplex test. This innovative test represents a major advancement in accessible molecular diagnostics.

The Metrix® COVID/Flu test simultaneously detects and differentiates SARS-CoV-2, Influenza A virus, and Influenza B virus in 20 minutes. Authorized for over-the-counter (OTC) use, it can be utilized in any environment, including at home and in CLIA-waived point-of-care (POC) settings.

“Molecular diagnostics are the gold standard for accuracy, but traditional systems are expensive, slow, and force molecular to be greatly underutilized. Metrix changes all that,” said Scott Ferguson PhD, CEO of Aptitude. “We built Metrix to dramatically expand the reach of molecular diagnostics by breaking cost and accessibility barriers. Our Metrix COVID/Flu test empowers individuals to get their own lab-quality results on the spot in their homes and enables healthcare providers to upgrade from existing molecular and antigen testing platforms while lowering total cost of care.”

Sign up for Blog Updates